Welcome to our dedicated page for CeriBell news (Ticker: CBLL), a resource for investors and traders seeking the latest updates and insights on CeriBell stock.
CeriBell, Inc. (CBLL) delivers innovative neurological care solutions through its AI-powered EEG platform, transforming acute diagnosis in emergency and critical care settings. This page provides authorized news updates and official announcements about the company's medical technology developments.
Access timely updates on FDA clearances, clinical trial results, and strategic partnerships that demonstrate CeriBell's leadership in point-of-care diagnostics. Investors and healthcare professionals will find verified information about product innovations, peer-reviewed study outcomes, and operational milestones.
Our curated news feed includes regulatory filings, technology enhancements, and hospital adoption updates, offering comprehensive insights into CeriBell's market position. Bookmark this page for direct access to primary source materials about seizure detection systems and neurological monitoring advancements.
Ceribell (Nasdaq: CBLL) announced FDA 510(k) clearance for its delirium monitoring solution on Dec 9, 2025, the first FDA-cleared device for continuous delirium screening at the bedside. The solution extends the Ceribell System to simultaneously support continuous seizure, electrographic status epilepticus (ESE), and delirium monitoring.
The delirium algorithm was validated in prospective studies of 225 adults in critical care. Ceribell has submitted a NTAP application to CMS to seek additional reimbursement for the new indication.
Ceribell (Nasdaq: CBLL) announced that the FDA granted 510(k) clearance on November 24, 2025 for its next‑generation Clarity algorithm to detect electrographic seizures from pre‑term neonates through adults. This clearance makes the Ceribell System the first and only AI‑powered point‑of‑care EEG cleared to detect seizures across all ages. The clearance was supported by EEG data from more than 700 patients and builds on a prior 510(k) clearance for a neonatal‑optimized headcap. The company positions the technology to enable faster bedside seizure detection in NICUs to reduce delays, transfers, and potential brain injury.
Ceribell (Nasdaq: CBLL) announced that Jane Chao, Ph.D., CEO and co-founder will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025.
The presentation is scheduled for 6:10 a.m. PST / 9:10 a.m. EST. A live and archived webcast will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York.
The session is scheduled for Thursday, November 20, 2025 at 5:30 a.m. PST / 8:30 a.m. EST. A live and archived webcast will be available in the company's Investor Relations section at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $22.6M, up 31% year-over-year; product revenue was $17.0M (+28%) and subscription revenue was $5.6M (+44%). Gross margin was 88% and gross profit was $19.9M. Operating expenses rose to $34.6M (+39%), driving a net loss of $13.5M (−$0.37 per share). Cash and marketable securities totaled $168.5M at quarter end. The company ended the quarter with 615 active accounts, appointed Erica Rogers to the board, and raised full‑year 2025 revenue guidance to $87M–$89M (~33%–36% growth).
Ceribell (Nasdaq: CBLL) will release its third quarter 2025 financial results after the close of trading on Tuesday, November 4, 2025.
Company management will host a conference call to discuss results at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Domestic callers can dial (800) 715-9871, international callers (646) 307-1963, and use access code 9394689. A live and archived webcast will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Ceribell (NASDAQ: CBLL), a medical technology company specializing in neurological diagnostics, has appointed Erica Rogers to its Board of Directors. Rogers brings over 30 years of experience in leading medical device companies, most notably as CEO of Silk Road Medical, where she grew the company from a 25-person startup to a 500-employee public company with $175 million in revenue.
Under Rogers' leadership, Silk Road Medical achieved FDA approval and commercial expansion, ultimately leading to its acquisition by Boston Scientific Corporation. Her appointment comes as Ceribell expands its point-of-care EEG system, which is currently used in over 550 hospitals to improve care for critically ill patients.
Ceribell (NASDAQ:CBLL) reported strong Q2 2025 financial results, with total revenue reaching $21.2 million, up 38% year-over-year. The medical technology company achieved an 88% gross margin and expanded to 584 total active accounts.
The company's performance was driven by product revenue of $15.9 million (up 38%) and subscription revenue of $5.3 million (up 41%). Despite these gains, Ceribell reported a net loss of $13.6 million ($0.38 per share) due to increased operating expenses. The company maintains a strong financial position with $177.4 million in cash and equivalents.
Following these results, Ceribell raised its full-year 2025 revenue guidance to $85-88 million, projecting 30-34% growth over 2024.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., will deliver a presentation on Tuesday, August 12, 2025, at 2:00 p.m. EST.
Investors can access both the live and archived versions of the presentation through the company's investor relations website at investors.ceribell.com.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has scheduled its Q2 2025 financial results release for August 5, 2025, after market close.
The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Investors can join via phone using the provided dial-in numbers and access code 7468193, or access the webcast through Ceribell's investor relations website.
FAQ
What is the current stock price of CeriBell (CBLL)?
What is the market cap of CeriBell (CBLL)?
